The battle to treat obesity is heating up as pharmaceutical companies push beyond the current blockbuster GLP-1 drugs. While Eli Lilly and Novo Nordisk currently lead the market with injections like Zepbound and Wegovy, a flood of competitors is racing to develop more convenient, effective, and tolerable options. With hundreds of millions of potential patients worldwide, the stakes are enormous for both public health and industry profits.
Current Leaders Strengthen Their Positions
Eli Lilly and Novo Nordisk continue to dominate but are not resting on their laurels. At the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans, both highlighted progress in oral formulations that could make treatment far more accessible.
Novo Nordisk reported impressive early uptake of its Wegovy pill, with over 3 million prescriptions filled in just five months. Eli Lilly has launched its own small-molecule oral option, Foundayo (orforglipron), offering patients a simple daily tablet instead of weekly injections.
Lilly is also advancing its ambitious triple agonist retatrutide, which targets GLP-1, GIP, and glucagon receptors. Phase 3 results have been striking: patients on the highest dose achieved an average 28% body weight loss, with nearly half shedding more than 30%. Company leaders see this as a game-changer for individuals with severe obesity (BMI over 40), potentially helping them reach a healthy weight range.
Challengers Bet on Innovation and Convenience
Several other drugmakers are carving out space with differentiated approaches focused on easier dosing and better side-effect profiles:
- Less Frequent Injections: Pfizer, through its $10 billion acquisition of Metsera, showcased mid-stage data on a monthly injectable. Amgen is developing candidates that could be dosed monthly or even quarterly. Amgen executives emphasize the appeal of treatments that allow patients to “not remember your disease” as often, improving long-term adherence.
- New Oral GLP-1 Options: Structure Therapeutics and AstraZeneca presented promising mid-stage results for their oral candidates. Successful Phase 3 trials could see these drugs hitting the market around 2029. Structure’s leadership views the crowded field positively, believing competition ultimately benefits patients and positioning itself as a strong contender in small-molecule orals.
- Alternative Pathways Beyond GLP-1: Zealand Pharma, partnering with Roche, highlighted its amylin analog petrelintide. It achieved nearly 11% weight loss with significantly lower rates of vomiting compared to current options — a major potential advantage for tolerability. Lilly is also progressing with its own amylin program, eloralintide, now in Phase 3.
Analysts estimate over 100–190 obesity drug candidates are in development across dozens of companies, including Viking Therapeutics and others exploring multi-agonists, small molecules, and entirely new mechanisms.
Market Opportunities and Remaining Hurdles
Obesity affects approximately 890 million people globally, with another 2.5 billion considered overweight, according to WHO data. This creates a massive addressable market, but challenges remain.
Pricing pressure is already evident, with Lilly and Novo cutting prices in response to competition from each other and compounding pharmacies. Insurance coverage is improving, including potential Medicare options that could bring out-of-pocket costs down to around $50 per month for eligible seniors.
Industry executives like Novo’s Mike Doustdar compare the future of obesity care to mental health treatment — moving away from one-size-fits-all solutions toward a broader spectrum of tailored therapies.
What This Means for Patients and the Future
The next generation of obesity drugs promises meaningful improvements: convenient pills, longer-lasting injections, reduced side effects, and potentially better outcomes for muscle preservation and related health conditions.
While Lilly currently holds an edge in injectables and early oral momentum, the race remains wide open. Increased competition is likely to drive down costs, expand access, and deliver more personalized treatment options.
For patients struggling with obesity and its complications, this surge in innovation offers real hope. For the pharmaceutical industry, success will depend on strong clinical data, efficient manufacturing, and favorable reimbursement policies.
The obesity drug landscape is evolving at breakneck speed. With more Phase 3 results and regulatory decisions on the horizon, the coming years could transform how we approach one of the biggest health challenges of our time. Stay tuned for the next breakthroughs that could reshape millions of lives.
About The Author
